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Conclusion: Although radiotherapy for painful bone 
metastases leads to a meaningful pain response, QoL does 
not improve after treatment. Initially, it remains stable 
followed by deterioration towards the end of life. 
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Purpose or Objective: The incidence of p16-overexpression 
and the role of human papillomavirus (HPV) in cutaneous 
head and neck squamous cell carcinoma (cHNSCC) is unclear. 
In the unknown primary setting, where cHNSCC is a potential 
putative site, p16 status is being used to guide management 
despite varying reports of its incidence in non-oropharyngeal 
sites.  
 
Material and Methods: 143 patients with cHNSCC lymph node 
metastases involving the parotid gland were evaluated for 
p16 expression by immunohistochemistry. Detection of 18 
high-risk HPV subtypes was performed using HPV RNA in situ 
hybridization on a subset of 59 patients. Results were 
correlated with clinicopathological features and outcomes 
 
Results: Median follow up time was 5.3 years. No differences 
were observed in clinicopathological factors based on p16 
status. p16 was positive, intermediate and negative in 45 
(31%), 21 (15%) and 77 (54%) of cases, respectively. No high-
risk HPV subtypes were identified, irrespective of p16 status. 
p16 status was not prognostic for overall (HR 1.08 95% CI 
[0.85 - 1.36], p=0.528), cancer-specific (HR 1.12 95% CI [0.77 
- 1.64], p=0.542) or progression-free survival (HR 1.03 95% CI 
[0.83 - 1.29], p=0.783). Distant metastasis free survival, 
freedom from locoregional failure and freedom from local 
failure were also not significantly associated with p16 status. 
 
Conclusion: p16 positivity is common but not prognostic in 
cHNSCC lymph node metastases. High-risk HPV subtypes are 
not associated with p16-positivity, and do not appear to play 
a role in this disease. HPV testing, in addition to p16-status in 
the unknown primary setting may provide additional 
information in determining a putative primary site. 
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Purpose or Objective: To investigate the prognostic 
significance of tumore-related leukocytosis (TRL) in cervical 
cancer patients treated with definitive radiotherapy 
 
Material and Methods: Between 1986 and 2012, 2,456 
patients with uterine cervical cancer (FIGO stage IA-IB 494, 
stage IIA-IIB 1530, stage IIIA-IIIB 394 and stage IVA 38) who 
received definitive radiotherapy (62.6%) or platinum-based 
chemoradiotherapy (37.4%) consisting of EBRT and ICBT were 
retrospectively analyzed. TRL was defined as WBC count of 
≥9,000/μL on ≥2 occasions at the time of diagnosis and during 
the course of treatment. The neutrophil/lymphocyte ratio 
(NLR) was defined as the absolute neutrophil count divided 
by the absolute lymphocyte count. Locoregional failure free 
survival (LRFFS) and overall survival (OS) were compared 
between patients with or without TRL. 
 
Results: Median age of all patients was 55 years (range, 21-
87) and the median follow-up time was 65.1 months (range, 
0.7-347.8). Among 2,456 patients included in this study, TRL 
was observed in 398 (16%) at the initial diagnosis. Patients in 
TRL(+) group were younger in age and had larger tumor, 
advanced FIGO stage and more common LN metastases (all p 
< 0.05). TRL (+) group showed relatively lower rate of 
complete remission (CR) (90% vs. 97%, p = 0.042).The 10-year 
LRFFS and OS for all patients were 84% and 78%, respectively. 
Compared to TRL(-) group, LRFFS and OS were significantly 
lower in TRL(+) group (10-yr LRFFS: 69% vs. 87%, p <0.001; 
10-yr OS: 63% vs. 81% p < 0.001). After propensity score 
matching by age, FIGO stage, tumor size, LN metastasis, 
histologic subtype and pretreatment hemoglobin (Pre Tx Hb), 
both groups were well matched. The LR control and OS rate 
of TRL (+) group was still significantly lower than those of 
TRL (-) group. In multivariate analysis, advanced FIGO stage, 
non-SqCCa, larger tumor size and TRL were identified as risk 
factors for LRFFS and OS (all p < 0.05). In addition, Pre Tx 
Hb, LN metastasis and high NLR (≥2.5) were also associated 
with poorer OS (all p < 0.05). Among patients with LRF 
(n=345), patients with TRL at the time of recurrence 
accounted for 26% and showed relatively poorer median OS (6 
vs. 12 months, p = 0.001). 
 
Conclusion: This study supports the aggressive nature and 
poor radiation response of cervical cancer with leukocytosis. 
Given the unfavorable features and higher probability of 
treatment failure, optimal therapeutic approach and careful 
monitoring for early detection of recurrence should be 
considered for these patients. 
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Purpose or Objective: Stage II testicular seminoma is highly 
curable with radiotherapy (RT) or multiagent chemotherapy 
(MACT). These modalities have not been prospectively 
compared. Due to the rarity of stage II seminoma, prior 
studies are limited by small sample size.  NCCN guidelines 
recommend RT as the preferred treatment for stage IIA, 
while EUA guidelines equally allow for RT or MACT.  Both 
guidelines are equivocal for stage IIB, and recommend MACT 
for stage IIC. 
 
